Scholarlink

<p>Rare urological tumors such as neuroendocrine prostate cancer, non-clear cell renal cell carcinoma, penile carcinoma, and non-urothelial bladder tumors are defined by low incidence, biological heterogeneity, and limited evidence-based treatment options. Molecular tumor boards (MTBs) have emerged as a&#xa0;key strategy to facilitate personalized therapy by integrating histopathological, genomic, and clinical data. This narrative review summarizes the current state of molecular approaches in rare urological malignancies, focusing on pathogenesis, clinical characteristics, and systemic treatment strategies. Special emphasis is placed on the potential of MTBs to identify relevant targets in aggressive or refractory cases and to initiate experimental treatments, such as antibody–drug conjugates (ADCs), immune checkpoint inhibitors (ICI), and molecularly targeted therapies. As tumor-agnostic approvals increase, comprehensive molecular profiling becomes essential, even in rare entities. MTBs thus represent an important tool for improving care in this complex patient population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapieoptionen bei seltenen urologischen Tumoren: Perspektiven durch molekulare Tumorboards

  • 期刊论文

  • 发表日期：

    2025年12月23日

查看全文
  • Steffen Rausch,
  • Isabel Heidegger,
  • Johannes Linxweiler,
  • Christoph Becker,
  • Günther Niegisch

摘要

Rare urological tumors such as neuroendocrine prostate cancer, non-clear cell renal cell carcinoma, penile carcinoma, and non-urothelial bladder tumors are defined by low incidence, biological heterogeneity, and limited evidence-based treatment options. Molecular tumor boards (MTBs) have emerged as a key strategy to facilitate personalized therapy by integrating histopathological, genomic, and clinical data. This narrative review summarizes the current state of molecular approaches in rare urological malignancies, focusing on pathogenesis, clinical characteristics, and systemic treatment strategies. Special emphasis is placed on the potential of MTBs to identify relevant targets in aggressive or refractory cases and to initiate experimental treatments, such as antibody–drug conjugates (ADCs), immune checkpoint inhibitors (ICI), and molecularly targeted therapies. As tumor-agnostic approvals increase, comprehensive molecular profiling becomes essential, even in rare entities. MTBs thus represent an important tool for improving care in this complex patient population.